Sartan Medications Settlement - Valsartan, Losartan, and Irbesartan

What happened

Multiple pharmaceutical manufacturers sold blood pressure medications (Valsartan, Losartan, and Irbesartan) that allegedly contained contamination with probable human carcinogens including N-nitrosodimethylamine (NDMA), nitrosamine impurities, and NMBA. The defendants have denied wrongdoing and denied that the contamination amounts were carcinogenic.

Do you qualify?

Individuals in the United States who paid for retail purchases of the affected medications. For Hetero Valsartan: purchased between May 1, 2018 and July 31, 2018. For Aurobindo Irbesartan: purchased from January 1, 2016 to present. For Vivimed Losartan: purchased with specific National Drug Codes.

What you can claim

Read from the official settlement notice. Confirm the terms that apply to you on the administrator's site before filing.

• Settlement payment from claim

  Class members who submit a Claim Form can receive a Settlement payment. Documentation should be submitted to support the claim if possible.

Who is in the class

You are a member of the Consumer Settlement Class if you are an individual in the United States and its territories and possessions who paid any amount of money for retail purchases of Valsartan finished drug formulations utilizing Hetero Process III Valsartan active pharmaceutical ingredient ("API") which was sold between May 1, 2018 to July 31, 2018. You are a member of the consumer Settlement Class if you are an individual in the United States and its territories and possessions who, from January 1, 2016 to the present, paid any amount of money for retail purchases of irbesartan finished drug formulations manufactured using Aurobindo irbesartan API that was manufactured using Aurobindo's IC Route of Synthesis ("IC ROS Irbesartan"). You are a member of the consumer Settlement Class if you are an individual in the United States and its territories and possessions who paid any amount of money for retail purchases of Vivimed Losartan finished drug formulations sold under the following impacted National Drug Codes ("NDCs"): 23155-644-09; 23155-644-10; 23155-645-03; 23155-645-09; 23155-645-10; 23155-646-03; 23155-646-09; and 23155-646-10 ("Impacted NDCs").

Quoted from the settlement notice.

How to file

Submit a Claim Form online at the settlement website or by mail by June 2, 2026. Submit documentation to support your claim if possible, including proof of purchase from your pharmacy if requested by the Settlement Notice Administrator.